RPRX Royalty Pharma Plc Class A

Royalty Pharma Announces Secondary Offering of Class A Ordinary Shares by Selling Shareholders

Royalty Pharma Announces Secondary Offering of Class A Ordinary Shares by Selling Shareholders
EN
13/10/2020

Underlying

RPRXRoyalty Pharma Plc Class A

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Royalty Pharma Plc Class A

RPRX Royalty Pharma ...

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Royalty Pharma plc and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 4 March 2026 in which we reassessed the appropriateness of the ratings in the context of...

RPRX ROYALTY PHARMA PLC CLASS A
03/06/26 March 6, 2026 1 EN
 PRESS RELEASE
Free
RPRX Royalty Pharma ...

Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head ...

Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company’s royalty business in Asia. Ken joins Royalty Pharma from Morgan Stanley, where he was Head of Asia Pacific Healthcare Investment Banking. Asia-based biotechnology companies are now prolific creators of innovative therapeutics. In 2...

March 2, 2026 1 EN
 PRESS RELEASE
Free
RPRX Royalty Pharma ...

Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed No...

Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaidZymeworks to retain 70% of royalties on Ziihera sales per the agreement, with full royalty rights reverting to Zymeworks once the royalty payments to Royalty Pharma have ceasedProceeds strengthen Zymeworks’ balance sheet with non-dilutive capital and support its stock repurchase program, potential strategic acquisitions, and cash ru...

March 2, 2026 1 EN
 PRESS RELEASE
Free
RPRX Royalty Pharma ...

Royalty Pharma to Present at TD Cowen’s 46th Annual Health Care Confer...

Royalty Pharma to Present at TD Cowen’s 46th Annual Health Care Conference NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 46th Annual Health Care Conference on March 3, 2026 at 1:10 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at . The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharm...

February 26, 2026 1 EN
 PRESS RELEASE
Free
RPRX Royalty Pharma ...

Royalty Pharma Reports Q4 and Full Year 2025 Results

Royalty Pharma Reports Q4 and Full Year 2025 Results Portfolio Receipts of $874 million in Q4 2025 and $3,254 million for FY 2025 Portfolio Receipts growth of 18% in Q4 2025 and 16% for FY 2025Net cash provided by operating activities of $827 million in Q4 2025 and $2,490 million for FY 2025Full year 2026 guidance: Portfolio Receipts expected to be $3,275 million to $3,425 million NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year 2025 and introduced full year 2026 guidance for Portfolio Rece...

February 11, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch